Purpose-built protein engineering services.
Simultaneous multi-property engineering.
Natural proteins function in their native context, but therapeutic and industrial applications demand properties that evolution never optimized for: elevated temperatures, non-physiological substrates or pH, extended shelf life. And while optimizing for these conditions, retaining high target specificity is difficult.
The result of our process is proteins, antibodies, and enzymes that perform reliably across the full operating envelope you specify: thermostability, solubility, specificity, affinity, catalytic efficiency, and ease of expression.
Many of these factors are also directly responsible for late-stage failures of clinical candidates. Instability, poor expression, aggregation, or insufficient potency do not have to be terminal - we identify the specific liability holding a molecule back, then generate a panel of variants with enhanced or adjusted performance, giving programs real options before they even enter the clinic.
What we address
High-affinity binders discovery.
Discovering a novel binding protein against a chosen target - one that avoids known immunogenicity liabilities, possesses kinetic properties suitable for your application, and remains manufacturable at scale - remains one of protein engineering's most common challenges. Traditional phage display, antibody libraries, and conventional scaffolds each have blind spots.
We maintain pressure on multiple properties simultaneously: binding kinetics, stability, expression, and manufacturability. The result is a binder that meets your requirements without compromises.
What we address
Reducing immunogenic liability without compromising potency.
A potent therapeutic protein that triggers strong immunogenicity in human subjects becomes clinically untenable. Whether your protein is inherently foreign, carries non-human sequence motifs, or bears post-translational modifications that trigger immune recognition, addressing immunogenic risk early dramatically improves development probability.
The goal is a molecule that retains full therapeutic potency with a substantially reduced immunogenic footprint.
What we address
Expression, production, and targeted modifications.
Our portfolio includes regular applied protein engineering services for clinical, industrial, or research purposes. We can produce recombinant proteins and antibodies at various scales, and take on engineering requests such as yield increase in a given expression host, a specific post-translational modification added or removed, or creating extensive point mutation libraries.